Clinicians treating ST-elevation myocardial infarction (STEMI) often struggle with outdated risk assessment tools. The NICVD-NQ risk score recently emerged as a contemporary solution to predict short-term major adverse cardiovascular events (MACE). Although existing scores like TIMI and GRACE remain popular, they often fail to capture the nuances of modern primary percutaneous coronary intervention (PCI) outcomes, particularly in South Asian populations. Consequently, this new predictive instrument offers a localized and updated approach to patient care.

Clinical Utility of the NICVD-NQ Risk Score

The development of the NICVD-NQ score addressed a critical gap in cardiology. Many traditional risk scores were derived during the fibrinolytic era or in high-income western settings. This limits their relevance for contemporary practice in India and neighboring regions. Specifically, this prospective study followed 2,839 patients at a major cardiac care center. The researchers sought to predict MACE over a median follow-up of approximately eight months. Notably, the model demonstrated an Area Under the Curve (AUC) of 0.772, indicating strong predictive performance.

Comparing Performance with Traditional Models

When researchers evaluated the NICVD-NQ risk score against established tools, the results were promising. The new model significantly outperformed the TIMI and PAMI scores. Furthermore, it showed a net reclassification improvement (NRI) that highlights its superior ability to correctly categorize patient risk. While its accuracy was comparable to the GRACE and CADILLAC scores, the NICVD-NQ score provides a more relevant alternative for regional clinicians. This enhanced predictive accuracy enables doctors to identify high-risk patients earlier and adjust treatment strategies accordingly.

Future Implications for STEMI Management

Integrating this tool into routine clinical practice could refine risk stratification after primary PCI. Since the study was conducted in Pakistan, the findings are highly applicable to the Indian demographic. Therefore, clinicians can utilize this instrument to bridge the gap between high-volume clinical settings and personalized patient monitoring. By moving beyond mortality-focused scores, healthcare providers can better manage the broader spectrum of cardiovascular events that impact long-term recovery.

Frequently Asked Questions

What are the primary components of the NICVD-NQ risk score?

The score is an additive model designed to predict short-term MACE, including re-infarction, heart failure, and stent thrombosis, by utilizing clinical variables specific to the contemporary primary PCI era.

How does the NICVD-NQ risk score compare to the GRACE score?

While the NICVD-NQ score outperformed TIMI and PAMI, it demonstrated predictive accuracy comparable to the GRACE and CADILLAC scores, making it a valuable alternative for South Asian clinical settings.

Can this score be used for long-term prognosis?

This specific study validated the score for short-term outcomes, with a median follow-up of 244 days. Further research may be required to assess its utility for long-term (multi-year) risk stratification.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Kumar R et al. Development and Validation of NICVD-NQ Score for Predicting Short-Term Outcomes After Primary PCI. Catheter Cardiovasc Interv. 2026 May 13. doi: 10.1002/ccd.70657. PMID: 42129582.

Kumar R, et al. Enhancing Predictive Precision: The NICVD-NQ Score for Short-Term Cardiovascular Risk After Primary PCI. J Am Coll Cardiol. 2024 Oct;84(16_S):TCT-810.

Ashraf T, et al. Clinical and procedural predictors and short-term survival of the patients with no reflow phenomenon after primary percutaneous coronary intervention. Int J Cardiol. 2019 Nov 1;294:27-31.